AU2020241963A1 - Treatment of cancers using sEphB4-HSA fusion proteins - Google Patents

Treatment of cancers using sEphB4-HSA fusion proteins Download PDF

Info

Publication number
AU2020241963A1
AU2020241963A1 AU2020241963A AU2020241963A AU2020241963A1 AU 2020241963 A1 AU2020241963 A1 AU 2020241963A1 AU 2020241963 A AU2020241963 A AU 2020241963A AU 2020241963 A AU2020241963 A AU 2020241963A AU 2020241963 A1 AU2020241963 A1 AU 2020241963A1
Authority
AU
Australia
Prior art keywords
cancer
treatment
sephb4
various embodiments
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020241963A
Other languages
English (en)
Inventor
Valery Krasnoperov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasgene Therapeutics Inc
Original Assignee
Vasgene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasgene Therapeutics Inc filed Critical Vasgene Therapeutics Inc
Publication of AU2020241963A1 publication Critical patent/AU2020241963A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020241963A 2019-03-17 2020-03-17 Treatment of cancers using sEphB4-HSA fusion proteins Pending AU2020241963A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962819642P 2019-03-17 2019-03-17
US62/819,642 2019-03-17
US201962819725P 2019-03-18 2019-03-18
US62/819,725 2019-03-18
PCT/US2020/023215 WO2020190977A1 (en) 2019-03-17 2020-03-17 Treatment of cancers using sephb4-hsa fusion proteins

Publications (1)

Publication Number Publication Date
AU2020241963A1 true AU2020241963A1 (en) 2021-11-04

Family

ID=72520496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020241963A Pending AU2020241963A1 (en) 2019-03-17 2020-03-17 Treatment of cancers using sEphB4-HSA fusion proteins

Country Status (8)

Country Link
US (1) US20220249621A1 (https=)
EP (1) EP3941512A4 (https=)
JP (1) JP7809324B2 (https=)
KR (1) KR20220015375A (https=)
CN (1) CN113939309A (https=)
AU (1) AU2020241963A1 (https=)
CA (1) CA3133437A1 (https=)
WO (1) WO2020190977A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139416A1 (en) * 2019-02-13 2020-08-20 Vasgene Therapeutics Inc Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer
EP4168019A4 (en) * 2020-06-17 2024-07-31 4C Biomed Services Ltd. ANTIBODIES AGAINST EPHB2 AND ITS USE IN COMBINATION THERAPY
KR20230106607A (ko) * 2020-10-11 2023-07-13 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법
CA3211742A1 (en) * 2021-03-18 2022-09-22 Valery Krasnoperov Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment
US20250123284A1 (en) * 2021-09-07 2025-04-17 Vasgene Therapeutics Inc Diagnostic methods for cancer using ephrinb2 expression
WO2023154948A1 (en) * 2022-02-14 2023-08-17 Vasgene Therapeutics Inc. Ephrin type-b receptor 4 (ephb4) agents and production thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2703136A1 (en) 2007-03-12 2008-09-18 Vasgene Therapeutics, Inc. Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
CA3139416A1 (en) * 2019-02-13 2020-08-20 Vasgene Therapeutics Inc Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer

Also Published As

Publication number Publication date
JP7809324B2 (ja) 2026-02-02
CN113939309A (zh) 2022-01-14
EP3941512A1 (en) 2022-01-26
EP3941512A4 (en) 2022-12-21
KR20220015375A (ko) 2022-02-08
US20220249621A1 (en) 2022-08-11
WO2020190977A1 (en) 2020-09-24
CA3133437A1 (en) 2020-09-24
JP2022525223A (ja) 2022-05-11

Similar Documents

Publication Publication Date Title
JP7809324B2 (ja) ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
EP3760229A2 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP2018516969A (ja) Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
JP2025060639A (ja) Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
TW202417479A (zh) 用於治療癌症之抗-pd-1活性劑、抗-tim-3活性劑及抗-lag-3活性劑之組合療法
US20240199758A1 (en) Method for allowing immune cells infiltration in tumors
KR20240149421A (ko) 암 면역요법을 위한 조성물 및 방법
KR20190051983A (ko) 암의 치료를 위한 abx196을 포함하는 조합물
WO2020081528A1 (en) Method and system for treating cancer utilizing tinagl 1
KR20170090406A (ko) 펩타이드-단백질 콘주게이트를 이용한 종양의 치료
US20250123284A1 (en) Diagnostic methods for cancer using ephrinb2 expression
US20240156908A1 (en) USE OF sEphB4-HSA FUSION PROTEIN AS A FIRST-LINE THERAPY IN CANCER TREATMENT
KR20250094749A (ko) 암을 치료하기 위한 il-12 유전자 요법 및 면역 체크포인트 억제제 조합물
WO2026057875A1 (en) Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy
CA3266426A1 (en) Anti-GDF15 antibodies used in a combination therapy of specific patient groups and a dosing regimen for the treatment of cancer